{
    "name": "pentosan polysulfate sodium",
    "comment": "Rx",
    "other_names": [
        "Elmiron"
    ],
    "classes": [
        "Analgesics",
        "Urinary"
    ],
    "source": "https://reference.medscape.com/drug/elmiron-pentosan-polysulfate-sodium-343348",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B",
            "Lactation: not known if excreted in breast milk, use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known if excreted in breast milk, use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Alopecia is associated with pentosan polysulfate and with heparin products; alopecia began within the first 4 weeks of treatment in clinical trials; ninety-seven percent (97%) of cases of alopecia reported were alopecia areata, limited to a single area on the scalp",
                "The drug has not been studied in patients with hepatic insufficiency; because there is evidence of hepatic contribution to elimination of drug, hepatic impairment may have an impact on pharmacokinetics of the drug; exercise caution when using drug in this patient population"
            ],
            "specific": [
                {
                    "type": "Retinal pigmentary changes",
                    "description": [
                        "Pigmentary changes in retina, reported as pigmentary maculopathy, identified with long-term use of drug",
                        "Although most cases occurred after 3 years of use or longer, cases have been seen with a shorter duration of use; while the etiology is unclear, cumulative dose appears to be a risk factor",
                        "Visual symptoms in reported cases included difficulty reading, slow adjustment to low or reduced light environments, and blurred vision",
                        "Visual consequences of pigmentary changes are not fully characterized",
                        "Use caution in patients with retinal pigment changes from other causes in which examination findings may confound appropriate diagnosis, follow-up, and treatment",
                        "Obtain detailed ophthalmologic history in all patients prior to starting treatment; consider testing if there is a family history of hereditary pattern dystrophy, genetic",
                        "For patients with pre-existing ophthalmologic conditions, a comprehensive baseline retinal examination (including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging) is recommended prior to starting therapy",
                        "A baseline retinal examination (including OCT and autofluorescence imaging) is suggested for all patients within six months of initiating treatment and periodically while continuing treatment; if pigmentary changes in retina develop, re-evaluate risks and benefits of continuing treatment, since these changes may be irreversible",
                        "Follow-up retinal examinations should be continued given that retinal and vision changes may progress even after cessation of treatment"
                    ]
                },
                {
                    "type": "Anticoagulant effects",
                    "description": [
                        "The drug is a weak anticoagulant (1/15 the activity of heparin) At a daily dose of 300 mg (n=128), rectal hemorrhage was reported as an adverse event in 6.3% of patients",
                        "Bleeding complications of ecchymosis, epistaxis, and gum hemorrhage reported",
                        "Patients undergoing invasive procedures or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to other therapies such as coumarin anticoagulants, heparin, tPA, streptokinase, high dose aspirin, or nonsteroidal anti-inflammatory drugs) should be evaluated for hemorrhage.",
                        "Patients with diseases such as aneurysms, thrombocytopenia, hemophilia, gastrointestinal ulcerations, polyps, or diverticula should be carefully evaluated before starting therapy",
                        "Exercise caution when administering therapy in patients who have a history of heparin-induced thrombocytopenia"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Alopecia",
            "percent": "4"
        },
        {
            "name": "Diarrhea",
            "percent": "4"
        },
        {
            "name": "Nausea",
            "percent": "4"
        },
        {
            "name": "Headache",
            "percent": "3"
        },
        {
            "name": "Abdominal pain",
            "percent": "2"
        },
        {
            "name": "Indigestion",
            "percent": "2"
        },
        {
            "name": "Rectal hemorrhage",
            "percent": null
        },
        {
            "name": "Elevated LFTs",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Partial thromboplastin time increased",
            "percent": null
        },
        {
            "name": "Prothrombin time increased",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Optic neuritis",
            "percent": null
        },
        {
            "name": "Retinal hemorrhage",
            "percent": null
        },
        {
            "name": "Pigmentary changes in the retina",
            "percent": null
        }
    ]
}